Amy Parison, who serves as senior vice president and chief financial officer of Editas Medicine, Inc. (NASDAQ: EDIT), reported the disposition of 474 shares of the company’s common stock on March 3, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The shares were sold at a weighted average price of $2.02, producing a total transaction value of $957. The sale prices for the shares ranged from $2.0050 to $2.0204.
Following the transaction, Parison directly holds 15,434 shares of Editas Medicine common stock.
The filing notes that the sale was carried out under a pre-arranged automatic sales plan adopted on July 7, 2022. The plan was executed to satisfy tax obligations associated with the vesting of restricted stock units that occurred on March 2, 2026. As disclosed, the transaction was therefore intended to address tax liabilities tied to RSU vesting rather than being an ad hoc decision by the insider.
At the time of the filing, Editas Medicine shares were trading at $2.19 and the company had a market capitalization of $213.8 million. An InvestingPro analysis included in the filing states that the stock appears undervalued at current price levels.
Investors seeking more detailed financial analysis and additional InvestingPro insights may consult the Pro Research Report, which is available to subscribers and offers expanded commentary and metrics on the company’s financial position.
Context and implications
The transaction reported by Parison is limited in scale, with a stated value of $957, and was executed under a pre-set plan tied to a tax obligation from RSU vesting. Because the sale was pre-arranged and narrowly defined in purpose, the filing provides limited direct insight into management’s broader view of the company’s valuation or near-term operational prospects.
InvestingPro’s characterization of Editas as appearing undervalued is noted in the report filed along with the transaction details; that assessment is presented as the platform’s analysis rather than a statement from company insiders.
Summary takeaways
- Parison sold 474 shares on March 3, 2026 at a weighted average price of $2.02, for a total of $957.
- The sale was executed under an automatic plan adopted July 7, 2022 to cover tax obligations from RSUs that vested March 2, 2026.
- After the sale Parison directly owns 15,434 shares; the stock trades at $2.19 with a market cap of $213.8 million, and InvestingPro’s analysis suggests the shares may be undervalued.